Recent Investment Analysts’ Ratings Changes for Sionna Therapeutics (SION)

Several analysts have recently updated their ratings and price targets for Sionna Therapeutics (NASDAQ: SION):

• 8/15/2026 – Sionna Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/10/2026 – Sionna Therapeutics was downgraded by Citigroup Inc. from “outperform” to “market perform”.
• 8/10/2026 – Sionna Therapeutics was downgraded by Lifesci Capital from “strong-buy” to “hold”.
• 8/10/2026 – Sionna Therapeutics was downgraded by JonesTrading from “strong-buy” to “hold”.
• 8/10/2026 – Sionna Therapeutics was downgraded by BTIG Research from “buy” to “neutral”.
• 8/10/2026 – Sionna Therapeutics was downgraded by Guggenheim from “buy” to “neutral”.
• 8/10/2026 – Sionna Therapeutics was downgraded by Citizens Jmp from “outperform” to “market perform”.
• 8/10/2026 – Sionna Therapeutics was downgraded by Raymond James Financial, Inc. from “strong-buy” to “market perform”.
• 8/10/2026 – Sionna Therapeutics was upgraded by Royal Bank Of Canada from “underperform” to “sector perform”. They now have a $5.00 price target on the stock.
• 8/10/2026 – Sionna Therapeutics was downgraded by Wedbush from “outperform” to “neutral”. They now have a $5.00 price target on the stock.
• 8/10/2026 – Sionna Therapeutics had its “hold” rating reaffirmed by Stifel Nicolaus. They now have a $7.00 price target on the stock.
• 8/7/2026 – Sionna Therapeutics had its price target raised by Guggenheim from $50.00 to $60.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Sionna Therapeutics had its “market perform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $59.00 price target on the stock.
• 8/5/2026 – Sionna Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In other news, Director Orbimed Advisors Llc sold 85,918 shares of the business’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the transaction, the director directly owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. The trade was a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the sale, the director owned 2,469,959 shares in the company, valued at $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 403,726 shares of company stock worth $18,259,354. 5.10% of the stock is owned by insiders.

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.